The platform – which deals with data from trial planning to post-market studies – now allows user to create separate dashboards and visualisations for specific needs, such as patient indications or trial regions.
The biopharma provider says the tool with improve pharmacovigilance as it is able to focus on safety-specific data, and will help simplify the patient enrollment process.
Laura Wilson, manager of corporate communication, told Outsourcing-Pharma.com: “This change is important because the navigation offers transparency into critical data at the study, program and portfolio levels.”
She added that regular update mean the client will have “near real-time” reporting.
“Quick and decisions can be made to ensure trial success,” she said, adding: “They will be able to detect, at an early stage, subtle but important signals which would have previously passed unnoticed.”
A gap in the market
In a statement, VP of integrated processes and technologies Thomas Grundstrom said the updates came about as a result of “gaps” in Quintiles’ data for managing studies.
Wilson said the programme is a result of planning with the customers. She said: “It is a topic that many of our customers and competitors have been discussing, debating, and promising for several years now.”
She added that Infosario is now the only programme to provide a complete one-stop-shop eClinical system with the ability to customise to suit specific needs.
“A small number of companies are trying to implement solutions in this market, but only Quintiles brings the full scope of capabilities that includes data analytics, and deep therapeutic and industry expertise together in one solution,” she said.
“For example, the Quintiles Infosario reporting and analytics platform is technology and system-independent. This makes it easy for customers to integrate with their existing systems and solutions.”